
Sign up to save your podcasts
Or


Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.
By BiotechTV4.3
66 ratings
Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.

3,374 Listeners

426 Listeners

1,644 Listeners

938 Listeners

125 Listeners

321 Listeners

213 Listeners

6,444 Listeners

61 Listeners

9,855 Listeners

86 Listeners

34 Listeners

19 Listeners

0 Listeners

4 Listeners

2 Listeners

5 Listeners

49 Listeners